Financial Performance - The company's operating revenue for Q3 2023 was ¥409,185,173.54, a decrease of 20.07% compared to the same period last year[5] - The net profit attributable to shareholders was ¥78,829,270.02, an increase of 18.47% year-on-year[5] - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥54,079,645.86, a decrease of 15.28% compared to the previous year[5] - Total operating revenue for Q3 2023 was CNY 1,465,941,311.21, a decrease of 11.06% compared to CNY 1,648,829,042.01 in Q3 2022[21] - Net profit for Q3 2023 was CNY 187,652,324.30, down 27.0% from CNY 257,198,189.23 in Q3 2022[22] - Basic earnings per share for Q3 2023 were CNY 0.1549, down from CNY 0.2142 in Q3 2022, a decrease of 27.7%[22] - The net profit of the merged entity before the merger was ¥187,652,324.30, down from ¥257,198,189.23 in the previous period[23] Cash Flow - Cash flow from operating activities for the year-to-date increased significantly to ¥391,002,276.99, up 814.03%[5] - Cash inflow from operating activities totaled ¥1,939,647,154.95, an increase of 15.4% compared to ¥1,680,056,558.66 in the previous period[23] - The net cash flow from operating activities was ¥391,002,276.99, a significant recovery from a negative cash flow of -¥54,760,163.91 in the previous period[23] - Cash outflow from investing activities was ¥329,978,441.76, down from ¥490,689,449.55 in the previous period[24] - The net cash flow from investing activities was -¥108,039,608.48, an improvement from -¥161,871,398.15 in the previous period[24] - Cash inflow from financing activities was ¥442,500,000.00, a decrease from ¥600,480,000.00 in the previous period[24] - The net cash flow from financing activities was -¥226,310,659.25, compared to a positive cash flow of ¥56,975,102.90 in the previous period[24] - The ending balance of cash and cash equivalents was ¥464,690,328.84, down from ¥508,855,227.02 in the previous period[24] Assets and Liabilities - The company's total assets at the end of the reporting period were ¥2,738,221,899.45, a decrease of 2.41% from the end of the previous year[5] - The company's total assets decreased to CNY 2,738,221,899.45 from CNY 2,805,938,488.48, reflecting a decline of 2.39%[20] - Total liabilities decreased to CNY 258,946,597.54, down 30.49% from CNY 372,530,210.51 in the previous year[20] - The total current assets decreased to ¥1,528,494,252.73 from ¥1,687,284,119.39, a decline of about 9.4%[18] - Long-term equity investments decreased to ¥2,892,232.31 from ¥5,344,460.80, a drop of approximately 46.1%[18] - The company's fixed assets decreased to ¥508,870,129.88 from ¥562,286,283.46, representing a decline of about 9.5%[18] Receivables and Inventories - Accounts receivable decreased by 51.97% compared to the beginning of the period, attributed to increased sales collections[9] - Accounts receivable decreased significantly to ¥271,420,391.44 from ¥565,080,441.81, indicating a reduction of about 52%[18] - Inventory rose to ¥674,946,988.77 from ¥536,483,390.67, reflecting an increase of approximately 25.8%[18] - The company reported a significant increase in other receivables, rising to ¥17,861,886.24 from ¥2,484,942.53, an increase of approximately 619%[18] Research and Development - Research and development expenditures increased by 47.53% compared to the beginning of the period, indicating a focus on innovation[9] - Research and development expenses increased to CNY 53,171,193.11, up from CNY 47,814,735.93, representing an increase of 11.06%[21] - The company plans to continue focusing on R&D and market expansion to drive future growth despite the current decline in revenue and profit[22] - The company’s development expenditures increased to ¥55,576,955.12 from ¥37,671,969.51, showing a growth of approximately 47.5%[18] Debt and Financing - Short-term borrowings decreased by 80% compared to the beginning of the period, reflecting reduced reliance on debt[10] - The net cash flow from financing activities decreased by ¥283,285,800 compared to the previous year, primarily due to repayment of short-term bank loans and stock repurchases[11] Other Information - The core employee stock ownership plan's lock-up period ended on September 5, 2023, with future decisions on stock sales pending market conditions[16] - The company is evaluating market conditions and shareholder intentions regarding the potential sale of stocks post-lock-up period[16] - The company did not undergo an audit for the third quarter report[25] - The company implemented new accounting standards starting in 2023, affecting the financial statements[25]

证券代码：002550 证券简称：千红制药 公告编号：2023-025 常州千红生化制药股份有限公司 关于 2022 年核心员工持股计划锁定期届满的提示性公告 2、本次员工持股计划的锁定期 根据《公司 2022 年核心员工持股计划（草案）》的规定，本次员工持股计划 存续期为不超过 24 个月，所受让的标的股票的锁定期为 12 个月，自公司将标的 股票过户至员工持股计划证券专用账户名下之日起算，即锁定期自 2022 年 9 月 6 日至 2023 年 9 月 5 日。 二、本次员工持股计划锁定期届满的后续安排 本公司及董事会全体成员保证信息披露内容的真实、准确、完 整，没有虚假记载、误导性陈述或重大遗漏。 常州千红生化制药股份有限公司（以下简称"本公司"或"公司"）于 2022 年 8 月 8 日分别召开了第五届董事会第八次会议、第五届监事会第七次会议，于 2022 年 8 月 24 日召开了 2022 年第一次临时股东大会，审议通过了《公司 2022 年核心员工持股计划（草案）及其摘要的议案》等相关议案，具体内容详见公司 于 2022 年 8 月 9 日、2022 年 8 月 25 日在《上海证券报》、《证券 ...

Financial Performance - The company's operating revenue for the first half of 2023 was CNY 1,056,756,137.67, a decrease of 7.05% compared to CNY 1,136,885,809.73 in the same period last year[25]. - The net profit attributable to shareholders decreased by 41.03% to CNY 119,025,836.94 from CNY 201,856,775.83 year-on-year[25]. - Basic and diluted earnings per share fell by 42.35% to CNY 0.0931 from CNY 0.1615 in the same period last year[25]. - The total profit for the first half of 2023 was CNY 134,760,019.43, a decline of 42.5% from CNY 234,109,504.90 in the same period last year[145]. - The total comprehensive income for the first half of 2023 was CNY 113,260,286.70, down from CNY 196,433,011.95 in the previous year[146]. - The company reported a total revenue of 14,900.45 million RMB, with a net profit of 1,562.63 million RMB for the reporting period[63]. - The company reported a total revenue of 800 million yuan for the first half of 2023, representing a 3.8% increase compared to the same period last year[159]. - The net profit attributable to shareholders was 288 million yuan, showing a growth of 6.3% year-over-year[159]. Cash Flow and Financial Position - The net cash flow from operating activities improved significantly, reaching CNY 107,384,874.81, compared to a negative cash flow of CNY -19,719,775.37 in the previous year, marking a 644.55% increase[25]. - The company's cash and cash equivalents increased by 177.17% to ¥15,911,646.27 from -¥20,619,567.56 year-on-year[47]. - The company reported a significant increase in retained earnings, amounting to 474 million yuan, reflecting strong operational performance[159]. - The company maintains a strong cash flow position, with cash reserves of RMB 200 million, ensuring sufficient liquidity for future investments[180]. - The ending balance of cash and cash equivalents as of June 30, 2023, was CNY 425,168,313.78, down from CNY 597,186,357.67 at the end of the first half of 2022[153]. Assets and Liabilities - The total assets of the company increased by 4.20% to CNY 2,923,921,830.93 compared to CNY 2,805,938,488.48 at the end of the previous year[25]. - The inventory level rose to ¥765,075,344, representing 26.17% of total assets, an increase from 19.12% last year[53]. - Total liabilities amounted to CNY 560,322,899.57, an increase from CNY 372,530,210.51 in the previous period[139]. - The total assets at the end of the reporting period were approximately 2.544 billion CNY, indicating a solid asset base[164]. Research and Development - Research and development expenses increased by 51.82% to ¥55,603,096.60, up from ¥36,625,001.01 in the previous year[46]. - The company has allocated 1,000,000 CNY for research and development of new technologies in the upcoming fiscal year[158]. - The company has allocated RMB 80 million for R&D in 2023, focusing on advanced biopharmaceutical technologies[180]. - The company is focusing on enhancing its research and development capabilities to innovate and improve product offerings[165]. Market Strategy and Expansion - The company operates a dual-market strategy focusing on both domestic and international markets, with a diversified sales model including self-operated and agency models[38]. - The company plans to enhance its marketing capabilities and product sales through innovative marketing models[67]. - The company plans to continue expanding its market presence and invest in new product development to drive future growth[158]. - The company is exploring potential mergers and acquisitions to enhance its competitive position in the market[158]. Environmental and Social Responsibility - The company adheres to various environmental protection laws and standards, including the Chemical Industry Volatile Organic Compounds Emission Standards and the Comprehensive Emission Standards for Air Pollutants[79]. - The company has implemented several environmental protection projects, including a pollution reduction technology transformation project and a comprehensive utilization project for ethanol[79]. - The company emphasizes the importance of employee welfare and adheres to labor laws, ensuring a harmonious labor relationship[84]. - The company donated RMB 1 million in cash and over RMB 5 million worth of medicines to the Red Cross Society of Changzhou, and committed to an annual donation of RMB 1 million for ten years to the Changzhou Charity Federation[86]. Shareholder Information - The company has maintained stable shareholding among its core management, with no changes in the number of shares held during the reporting period[75]. - The total number of ordinary shareholders at the end of the reporting period is 89,263[123]. - The company has a core employee stock ownership plan with 30 million shares allocated[125]. - The company distributed a cash dividend of 1.2 RMB (including tax) for every 10 shares to all shareholders, resulting in a total cash dividend of 720,000 RMB for the first employee stock ownership plan and 3.6 million RMB for the 2022 core employee stock ownership plan[76].

| 答：你好，公司目前除了参与国家第八批集采以外， | | --- | | 地方集采没有新情况。 | | 20、107 除了对应急性髓系白血病外，公司还有计划 | | 开发其他疾病治疗吗？ | | 答：公司正在紧锣密鼓地进行其他适应症的开发，正 | | 在临床前试验阶段，谢谢。 | | 21、去年的业绩突飞猛进，是一个良好的开始，请问 | | 疫情放开后，公司的销售平台是否有新的渠道进行推 | | 广？业绩是否能在去年的基础上实现增长？还有一 | | 个就是股价问题，公司的股价常年偏低，让投资者很 | | 失望，公司的领导层有何感想？ | | 答：你好，公司今年的主营业绩会持续增长，目前公 | | 司的股价没有反映公司的价值。 | | 22、公司负债率比较低，资金比较充裕，在确保公司 | | 流动资金周转的情况下，可否在每年的利润中拿出一 | | 部分资金（比如 10-30%）回购股份，然后注销呢？这 | | 样可以提高公司股份的内在价值。现金利润可以少 | | 分。敬请公司董事会考虑，谢谢。 | | 答：谢谢建议。 | | 23、今年业绩预计会怎么样？ | | 答：公司会持续经营好主营业务，力争保持业绩的持 ...

Financial Performance - The company's revenue for Q1 2023 was CNY 608,218,905.42, representing a 10.14% increase compared to CNY 552,220,533.56 in the same period last year[5] - Net profit attributable to shareholders decreased by 32.98% to CNY 85,946,847.70 from CNY 128,247,521.34 year-on-year, primarily due to a high base effect from last year's compensation received for land acquisition[8] - The company reported a decrease in operating income of CNY 58.01 million compared to the previous year, mainly due to a reduction in non-operating income[9] - Net profit for Q1 2023 was CNY 83,549,827.62, a decrease of 33.67% from CNY 125,796,128.32 in Q1 2022[22] - The company reported a total comprehensive income of CNY 83,505,000.50 for Q1 2023, compared to CNY 126,448,478.68 in Q1 2022, indicating a decline of 33.94%[22] Cash Flow - The net cash flow from operating activities was negative at CNY -28,080,310.76, a decrease of 130.53% compared to CNY 91,973,048.64 in the previous year[5] - The total cash inflow from operating activities was CNY 717,640,499.05, an increase from CNY 535,125,534.57 in the previous period, representing a growth of approximately 34%[23] - The net cash outflow from operating activities was CNY -28,080,310.76, compared to a net inflow of CNY 91,973,048.64 in the same period last year[23] - Cash inflow from investment activities totaled CNY 51,340,000.00, slightly up from CNY 49,488,572.06 in the previous year[23] - The net cash outflow from investment activities was CNY -107,460,996.87, a significant decrease from a net inflow of CNY 5,965,581.15 in the previous period[23] - Cash inflow from financing activities was CNY 200,000,000.00, an increase from CNY 106,677,500.00 in the previous year, marking an increase of approximately 87%[24] - The net cash flow from financing activities was CNY 199,080,789.21, compared to CNY 105,710,814.66 in the same period last year[24] - The total cash and cash equivalents at the end of the period were CNY 470,466,348.14, down from CNY 819,179,841.19 in the previous year[24] - The company experienced a negative impact of CNY -2,329,800.95 from exchange rate fluctuations on cash and cash equivalents[24] - The cash outflow for purchasing goods and services was CNY 580,833,369.71, significantly higher than CNY 285,911,340.92 in the previous year[23] Assets and Liabilities - The company's total assets increased by 9.28% to CNY 3,066,259,293.87 from CNY 2,805,938,488.48 at the end of the previous year[5] - The total assets of the company as of Q1 2023 were CNY 3,066,259,293.87, compared to CNY 2,805,938,488.48 at the end of Q1 2022, reflecting a growth of 9.27%[19] - The company's total liabilities increased to CNY 549,346,015.40, up 47.43% from CNY 372,530,210.51 in the previous year[19] - The equity attributable to shareholders of the parent company rose to CNY 2,536,256,250.79, an increase of 3.51% from CNY 2,450,354,230.21 in Q1 2022[19] - The company’s total non-current assets amounted to CNY 1,000,000,000.00, reflecting a stable investment in long-term growth[17] Research and Development - Research and development expenses grew by 83.32% compared to the beginning of the period, indicating increased investment in R&D projects[9] - R&D expenses increased significantly to CNY 20,590,742.37, up 83.56% from CNY 11,231,856.32 in the previous year[21] - The company received approval for the clinical trial of its new drug QHRD107, which will be tested in combination with Venetoclax and/or Azacitidine for treating acute myeloid leukemia (AML)[15] - The company plans to conduct a Phase II clinical trial for QHRD107, indicating ongoing investment in research and development[15] Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 100,348, with the largest shareholder holding 19.96% of the shares[12] - Basic and diluted earnings per share for Q1 2023 were CNY 0.0672, down from CNY 0.1026 in the same period last year[22] - The first phase of the employee stock ownership plan "Qianhong Pharmaceutical No. 1" has completed its lock-up period as of March 30, 2023[15] Inventory and Borrowings - Inventory levels rose by 32.16% as a result of increased stockpiling of key raw materials[9] - Inventory rose significantly to CNY 709,033,420.43 from CNY 536,483,390.67, marking an increase of approximately 32.1%[17] - The company's short-term borrowings increased by CNY 200.73 million, primarily due to the need for working capital for production[9]

Financial Performance - The company's operating revenue for 2022 was ¥2,303,547,790.85, representing a 22.86% increase compared to ¥1,874,936,527.14 in 2021[23]. - The net profit attributable to shareholders for 2022 was ¥323,414,382.52, a significant increase of 78.60% from ¥181,079,595.35 in 2021[23]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥258,203,416.75, up 107.65% from ¥124,346,294.60 in 2021[23]. - The basic earnings per share for 2022 was ¥0.25, a 66.67% increase from ¥0.15 in 2021[23]. - The total assets at the end of 2022 were ¥2,805,938,488.48, an 11.86% increase from ¥2,508,397,996.17 at the end of 2021[23]. - The total revenue for 2022 was approximately CNY 2.30 billion, representing a year-on-year increase of 22.87%[64]. - The biopharmaceutical segment accounted for ¥2,298,314,839.0, or 99.77% of total revenue, with a growth of 22.70% from ¥1,873,089,854.4 in the previous year[63]. - The raw material drug series generated ¥1,116,796,518.1, making up 48.48% of total revenue, with a significant increase of 68.37% from ¥663,303,530.81 in 2021[63]. - The formulation drug series reported revenue of ¥1,181,518,320.9, which is a slight decline of 2.34% compared to ¥1,209,786,323.6 in the previous year[63]. - The company reported a revenue of 2.304 billion yuan in 2022, an increase of 22.86% year-over-year, and a net profit of 320 million yuan, up 71.68% from the previous year[49]. Cash Flow and Dividends - The company reported a negative cash flow from operating activities of ¥71,473,850.55 in 2022, a decline of 169.02% compared to a positive cash flow of ¥103,560,504.98 in 2021[23]. - The company distributed a cash dividend of RMB 1.2 per 10 shares, totaling RMB 153,576,000, based on a total share capital of 1,279,800,000 shares[149]. - The total distributable profit for the company at the end of the reporting period was RMB 860,216,483.41, with the cash dividend representing 100% of the profit distribution[149]. - The company’s cash dividend policy was compliant with its articles of association and shareholder resolutions[147]. - The total cash dividend amount was confirmed by the auditing firm, ensuring transparency in the financial reporting[149]. Research and Development - The company applied for 14 invention patents in the field of biopharmaceutical innovation in 2022, indicating a strong focus on R&D[50]. - The R&D department is prioritizing the development of new injection formulations and advanced drug delivery systems[122]. - The company has established partnerships with research institutions to foster innovation and accelerate product development[124]. - The number of R&D personnel decreased by 7.10% to 170 in 2022 from 183 in 2021[75]. - Total R&D investment rose by 20.11% to ¥101,175,955.22 in 2022, compared to ¥84,236,292.50 in 2021[75]. Market Position and Strategy - The company is positioned as a leading player in the biopharmaceutical sector, focusing on innovative drug development and expanding both domestic and international markets[34]. - The company aims to enhance its core competitiveness through innovation and is actively developing high-value products for export[35]. - The company is actively expanding its international market presence, particularly in the heparin sodium raw material drug sector, maintaining a leading position in export sales among domestic enterprises[56]. - The company has established a professional international marketing team and a marketing network in countries such as the USA, Germany, France, Italy, and Japan, focusing on both raw material and high-value product exports[44]. - The company aims to develop the Yiguan product line as a new economic growth point, focusing on the promotion of biocatalytic therapy in the chronic disease medical landscape[48]. Corporate Governance and Management - The company emphasizes the importance of independent directors who play a crucial role in major decision-making and protecting the interests of minority shareholders[109]. - The company has established an internal audit department with 2 dedicated auditors to oversee economic operations and internal controls[110]. - The board of directors includes members with extensive industry experience, ensuring informed decision-making and governance[123]. - The company has established a comprehensive quality assurance system, ensuring the safety and quality of its pharmaceutical products, with no serious quality safety incidents reported over the years[172]. - The company has maintained a harmonious labor relationship, providing various social insurances and opportunities for employee development, enhancing overall employee satisfaction and corporate cohesion[170]. Environmental Responsibility - The company has implemented an ISO 14001 environmental management system since 2008, focusing on effective waste management and energy efficiency in its new facilities[172]. - The company invested approximately RMB 4.9 million in environmental protection measures, including pollution treatment facilities[168]. - The company has established automatic monitoring systems for wastewater discharge, including COD, total nitrogen, pH, and flow rate measurements[166]. - The company has implemented emergency response plans for environmental incidents, with the latest updates filed with local environmental authorities[167][168]. - The company reported no administrative penalties related to environmental issues during the reporting period[169]. Employee Development and Compensation - The total number of employees at the end of the reporting period was 1,102, with 949 in the parent company and 153 in major subsidiaries[143]. - The company has established a competitive compensation system based on job responsibilities and performance, aiming for fairness and efficiency[144]. - Various training programs are provided for new and existing employees, including mentorship and specialized training in management and technical skills[145]. - The company emphasizes the development of a high-quality management team through MBA training for senior management[145]. - The management team includes experienced professionals with backgrounds in engineering, economics, and pharmaceuticals, enhancing the company's strategic capabilities[123].